The company has invested major resources in R&D to better understand how beta-1,3/1,6- glucan modulates immune mechanisms and can be utilized to treat or prevent immune related diseases.
Biotec Pharmacon and Biotec BetaGlucans have experienced increased interest for the company’s beta-1,3/1,6-glucan products. This is certainly the result of the growing awareness within biomedical and clinical research societies that substances like beta-1,3/1,6-glucan with immune modulating abilities have notable potentials in treatment of immune related disorders and diseases.
Besides a comprehensive scientific foundation, the company has years of experience and efficacy documentation with its proprietary beta-1,3/1,6-glucan products used in animal husbandry and veterinary medicine. The company has regarded this lead to be sufficiently strong to justify an ambitious development program with its most promising drug candidate, soluble beta-1,3/1,6-glucan (SBG).
Biotec Pharmacon has previously developed a portfolio of beta-1,3/1,6-glucan products that for several years were sold in the animal health markets world-wide under the brand name MacroGard®. The experience of use and documentation of efficacy and safety on these products formed a sound foundation for further development of the company’s products. The Animal Health division was divested from the company in 2008. The company also developed consumer products under the trade-names NBG®, Immutol® and Immuderm®. The products have been available for several years in USA, Japan and Norway . The Consumer Health division was divested from the company in 2009.